Medtronic heads into its September 1 earnings report with the analyst community more constructive than it has been in months — a sharp contrast to a stock that is still finding its footing.
The most telling pre-earnings signal is analyst momentum. TD Cowen raised its target to $110 on August 28, just a day after Needham lifted to $114 — both maintaining Buy ratings and both moving in the same direction within 48 hours of the print. That follows UBS upgrading to Buy in late July with a $100 target. The consensus mean now sits at $98.84 against a current price of $91.23, implying roughly 8% upside on average. Not every analyst is aligned: Goldman Sachs holds a Neutral rating with an $83 target, and earlier in the quarter both Goldman and Bernstein trimmed targets after the June results disappointed. The net picture is a Street that has turned more positive but is not uniformly committed.
The fundamental debate centers on execution. Bulls point to Medtronic's diversified portfolio across cardiac, neuromodulation, and surgical categories, and a forward earnings momentum score that ranks in the 95th percentile across the universe — suggesting analysts expect meaningful EPS growth over the next twelve months. The bear argument is narrower but credible: reimbursement pressure, a track record of inconsistent execution, and the risk that revenue growth stays below 5% if new product launches disappoint. Recent results offered some comfort — the August quarter produced an earnings beat with the stock rallying nearly 4% on the day, while the June print delivered an even sharper 11% one-day move. Neither reaction faded quickly; five-day returns held positive after both events.
Short sellers have largely stepped aside heading in. Short interest has dropped more than 27% over the past month to just 1.1% of the free float — barely worth mentioning as a directional signal. Borrow availability is essentially unlimited, with no constraint whatsoever on anyone looking to initiate a short position. Cost to borrow is minimal at 0.43%. Options positioning is equally subdued: the put/call ratio at 0.61 is slightly below its 20-day average of 0.64, meaning options traders are not reaching for downside protection ahead of the release. Together, these signals describe a market that is not particularly worried about a negative surprise.
The September print will therefore test whether the renewed analyst optimism — and those strong prior-quarter reactions — reflects a genuine inflection in Medtronic's growth profile, or whether guidance remains too cautious to justify targets that now sit meaningfully above the current share price.
See the live data behind this article on ORTEX.
Open MDT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
